Molecular Diagnostics Market (US-specific Market Assessment) - Global Forecast upto 2024
  • ID: 1237
  • March 22, 2018
  • 130 pages
  • Infoholic Research

Global Molecular Diagnostics Market (US-specific Market Assessment) – Drivers, Restraints, Opportunities, Trends, and Forecasts: 2018–2024
Overview: Molecular diagnostics is the branch of clinical pathology or laboratory medicine that utilizes various molecular biology techniques to diagnose diseases, predict disease course, select treatments, and monitor the effectiveness of therapies. These tests are performed mainly to examine the existence of the disease in blood, tissue, or even in bones. The importance of nucleic acids and other cellular biomarkers in defining the vital cellular process has facilitated medical advancements in the diagnosis of various diseases. Early diagnosis of the disease is one of the key advantages of this technology. The capacity of molecular diagnostics to systematize molecular reactions for the enhancement of the clinical diagnosis has put healthcare in the front line. According to the estimation of the American Cancer Society, around 1,688,780 new cancer cases were diagnosed, and 600,920 people died due to cancer in 2017. According to the study by World Health Organization (WHO), approximately 14 million new cancer cases were diagnosed in 2017 and is expected to grow by about 70% over the next 2 decades. The outbreak of swine flu in Myanmar and India, in 2017, increased the demand for diagnosis in the Asia Pacific region. It is noticed that there is a considerable rise in the number of cases reported in 2017 when compared to 2016.
The market for molecular diagnostics is driven by increasing prevalence of infectious and other lifestyle diseases, increasing demand for non-invasive biomarker-based tests, growing adoption of point-of-care testing, and high growth of the market in emerging countries. Increasing number of mergers & acquisitions and growing significance of companion diagnostics are providing opportunities for the market growth. Low awareness about standardization, stringent regulatory approval process, and lack of skilled labors are hampering the market growth.
Market Analysis: The global molecular diagnostics market is estimated to witness a CAGR of 8.7% during the forecast period 2018–2024. The US occupied a dominant market share, i.e., 32% in 2017, and is expected to grow at a CAGR of 8.4% during the forecast period 2018–2024. The market is analyzed based on four segments – applications, technologies, end-users, and regions.
Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America is the major shareholder, followed by Europe, in the global molecular diagnostics market with the US contributing to significant market revenue. Increasing incidences of disease and organ transplantation in the US along with increasing funding by government & private players and increased adoption of personalized medicine in clinical practices are few of the factors driving the US molecular diagnostics market growth. Various countries in the Americas region are taking initiatives for the elimination of viral hepatitis, but the major challenge remains in the diagnosis of the disease. This is providing an opportunity for manufacturers to enhance their market presence. The Asia Pacific region is expected to witness the fastest growth rate due to the large patient pool, increasing awareness, and rising healthcare expenditure.
Technology Analysis: PCR occupied significant share in the global molecular diagnostics market in 2017. PCR is a gold standard technique for DNA amplification and is the primary technique conducted prior to any molecular diagnostic examination. Next-generation sequencing and microarray are expected to grow at the fastest rate during the forecast period.
Application Analysis: Among various application areas, the infectious disease application occupied the largest share in 2017 and cancer application is expected to grow at the highest growth rate during the forecast period. A large number of patients suffering from hospital-associated infection, sexually transmitted infection (STI), hepatitis, respiratory infection, pathogen ID detection, and others is fostering the market growth. Increasing incidence of cancer globally makes it the fastest growing application segment during the forecast period.
Key Players: F. Hoffmann-La Roche, Hologic, Inc., Danaher Corporation, Abbott Laboratories, and Siemens Healthineers Inc. are the key players in the market. Becton Dickenson and Company, bioMerieux S.A., Bio-Rad Laboratories, Inc., Qiagen NV, Grifols, S.A, Thermo Fisher Scientific, Sysmex Corporation, and Myriad Genetics are few predominate & niche players.
Competitive Analysis: Polymerase Chain Reaction (PCR) occupied a significant share in the molecular diagnostics market. The emerging players are focusing on developing NGS and microarray technology to have the edge in the market. The increasing importance of molecular diagnostic tests has resulted in the launch of new tests and also increased acquisition, strategic partnership, and funding to develop new tests and technologies. For instance, in April 2018, NanoString Technologies, Inc. launched a Breast Cancer 360 (BC 360) research panel. In July 2017, MDxHealth SA announced the commercial launch of its AssureMDx for bladder cancer test in the US as a laboratory developed test. Illumina recently started a new company, named GRAIL, for liquid biopsy. It invested $100 million and raised another $900 million through public funding to develop new non-invasive tests for cancer diagnosis.
Benefits: The report provides complete details about the usage and adoption rate of molecular diagnostics in various therapeutic verticals and regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives the complete information about the key business opportunities to key stakeholders to analyze before investing or expanding the business in this market.
Key Stakeholders:

Table of Content
1 INDUSTRY OUTLOOK
1.1 Industry overview
1.2 Total addressable market
2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions
3 Market Snapshot
3.1 Market Definition – Infoholic Research
3.2 Basic Steps of Molecular diagnostics
3.3 Segmented Addressable Market (SAM)
3.4 Major Trends in the Molecular Diagnostics Market
3.5 Related Markets
3.5.1 Liquid Biopsy
3.5.2 Point-of-Care diagnostics
3.5.3 Immunoassays
3.5.4 Clinical Chemistry
4 Market Outlook
4.1 Evolution iof Molecular Diagnostics
4.2 Market segmentation
4.3 PEST Analysis
4.4 Porter 5(Five) Forces
5 Market Characteristics
5.1 DRO – Global Molecular Diagnostics Market Dynamics
5.1.1 Drivers
5.1.1.1 Rising Prevalence of Infectious Disease
5.1.1.2 Growing Adoption of Point-of-care Testing
5.1.1.3 Increasing Demand for Biomarker-based Tests
5.1.1.4 High Growth of the Market in Emerging Countries
5.1.2 Opportunities
5.1.2.1 Growing Significance of Companion Diagnostics
5.1.2.2 Increase in Number of Mergers and Acquisitions
5.1.2.3 Increased Adoption of DNA Probe-based Diagnostics
5.1.3 Restraints
5.1.3.1 Stringent Regulatory Approvals
5.1.3.2 Lack of Skilled Labors
5.2 DRO – Impact Analysis
5.3 Key Stakeholders
6 Technology: Market Size and Analysis
6.1 Overview
6.2 PCR
6.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.4 Microarray
6.5 Hybridization
6.6 DNA sequencing
6.7 Others
7 Application: Market Size and Analysis
7.1 Overview
7.2 Oncology
7.2.1 Breast cancer
7.2.2 Colorectal cancer
7.2.3 Prostate cancer
7.2.4 Other cancers
7.3 Blood testing
7.4 Infectious Disease
7.5 Genetic Testing
7.6 Tissue Typing
7.7 Others
8 End Users: Market Size and Analysis
8.1 Overview
8.2 Hospitals
8.3 Reference Laboratories
8.4 Others
9 Regions: Market Size and Analysis
9.1 Overview
9.2 North America
9.3 Overview: US Molecular Diagnostics Market
9.4 Major Trends in the US Molecular Diagnostics Market
9.5 DRO – US Molecular Diagnostics Market Dynamics
9.6 Technology: US molecular Diagnostics Market
9.7 Application: US Molecular Diagnostics Market
9.8 Key companies of US molecular diagnostics market
9.9 Europe
9.9.1 UK 58
9.9.2 Germany
9.10 Asia Pacific
9.10.1 India
9.10.2 China
9.10.3 Japan
9.11 Rest of the World
9.11.1 Brazil
9.11.2 Mexico
9.11.3 Africa
10 Competitive Landscape
10.1 Overview
11 Vendor Profiles
11.1 Danaher Corporation
11.1.1 Overview
11.1.2 Business Units
11.1.3 Geographic Presence
11.1.4 Business Focus
11.1.5 SWOT Analysis
11.1.6 Business Strategies
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 Overview
11.2.2 Business Units
11.2.3 Geographic Revenue
11.2.4 Business Focus
11.2.5 SWOT Analysis
11.2.6 Business Strategies
11.3 ABBOTT LABORATORIES
11.3.1 Overview
11.3.2 Business Unit
11.3.3 Geographic Presence
11.3.4 Business Focus
11.3.5 SWOT Analysis
11.3.6 Business Strategy
11.4 Hologic Inc.
11.4.1 Overview
11.4.2 Business Unit
11.4.3 Geographic Presence
11.4.4 Business Focus
11.4.5 SWOT Analysis
11.4.6 Business Strategy
11.5 Siemens Healthineers (Siemens AG)
11.5.1 Overview
11.5.2 Business Units
11.5.3 Geographic Presence
11.5.4 Business focus
11.5.5 SWOT analysis
11.5.6 Business Strategy
12 Companies to Watch For
12.1 Qiagen N.V.
12.1.1 Overview
12.2 Bio-Rad Laboratories
12.2.1 Overview
12.3 Myriad Genetics Inc.
12.3.1 Overview
12.4 Thermo Fisher Scientific
12.4.1 Overview
12.5 bioMerieux S.A.
12.5.1 Overview
12.6 Beckton Dickinson and Company
12.6.1 Overview
12.7 Grifols S.A.
12.7.1 Overview
12.8 Sysmex Corporation
12.8.1 Overview
13 Annexure
13.1 Abbreviations

Tables
TABLE 1 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY APPLICATION, 2017–2024 ($MILLION) 34
TABLE 2 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE BY REGIONS, 2017–2024 ($MILLION) 49
TABLE 3 OTHER PROMINENT VENDORS IN THE MARKET 65
TABLE 4 DANAHER CORPORATION: OFFERINGS 67
TABLE 5 DANAHER CORPORATION: RECENT DEVELOPMENTS 69
TABLE 6 F. HOFFMANN-LA ROCHE LTD.: PRODUCT OFFERINGS 75
TABLE 7 F. HOFFMANN-LA ROCHE LTD.: RECENT DEVELOPMENTS 78
TABLE 8 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 85
TABLE 9 ABBOTT LABORATORIES: RECENT DEVELOPMENTS 87
TABLE 10 HOLOGIC INC.: PRODUCT OFFERINGS 93
TABLE 11 HOLOGIC INC: RECENT DEVELOPMENTS 94
TABLE 12 SIEMENS HEALTHINEERS: PRODUCT OFFERINGS 101
TABLE 13 SIEMENS HEALTHINEERS: RECENT DEVELOPMENTS 102
TABLE 14 QIAGEN N.V.: SNAPSHOT 108
TABLE 15 QIAGEN N.V.: RECENT DEVELOPMENTS 108
TABLE 16 BIO-RAD LABORATORIES: SNAPSHOT 112
TABLE 17 BIO-RAD LABORATORIES: RECENT DEVELOPMENTS 112
TABLE 18 MYRIAD GENETICS: SNAPSHOT 114
TABLE 19 MYRIAD GENETICS: RECENT DEVELOPMENTS 114
TABLE 20 THERMO FISHER SCIENTIFIC: SNAPSHOT 116
TABLE 21 THERMO FISHER SCIENTIFIC: RECENT DEVELOPMENTS 116
TABLE 22 BIOMERIEUX S.A.: SNAPSHOT 120
TABLE 23 BIOMERIEUX S.A.: RECENT DEVELOPMENTS 121
TABLE 24 BECTON DICKINSON AND COMPANY: SNAPSHOT 123
TABLE 25 BECTON DICKENSON AND COMPANY: RECENT DEVELOPMENTS 124
TABLE 26 GRIFOLS S.A.: SNAPSHOT 125
TABLE 27 GRIFOLS, S.A.: RECENT DEVELOPMENTS 125
TABLE 28 SYSMEX CORPORATION: SNAPSHOT 127
TABLE 29 SYSMEX CORPORATION: RECENT DEVELOPMENTS 127


Charts
CHART 1 RESEARCH METHODOLOGY OF GLOBAL MOLECULAR DIAGNOSTICS MARKET 13
CHART 2 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE, 2017–2024 ($MILLION) 17
CHART 3 SEGMENTATION OF GLOBAL MOLECULAR DIAGNOSTICS MARKET 20
CHART 4 PEST ANALYSIS OF GLOBAL MOLECULAR DIAGNOSTICS MARKET 21
CHART 5 PORTER 5 FORCES ON GLOBAL MOLECULAR DIAGNOSTICS MARKET 22
CHART 6 DRO – IMPACT ANALYSIS OF GLOBAL MOLECULAR DIAGNOSTICS MARKET 26
CHART 7 KEY STAKEHOLDERS OF MOLECULAR DIAGNOSTICS MARKET 27
CHART 8 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY SEGMENTATION, 2017 (%) 28
CHART 9 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%) 32
CHART 10 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE IN ONCOLOGY SEGMENT, 2017–2024 ($MILLION) 35
CHART 11 GLOBAL ONCOLOGY MARKET SHARE, 2017 (% SHARE) 36
CHART 12 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE IN BLOOOD TESTING SEGMENT, 2017–2024 ($MILLION) 39
CHART 13 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE IN INFECTIOUS DISEASES SEGMENT, 2017–2024 ($MILLION) 41
CHART 14 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE IN GENETIC TESTING SEGMENT, 2017–2024 ($MILLION) 42
CHART 15 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE IN TISSUE TYPING SEGMENT, 2018–2024 ($MILLION) 43
CHART 16 GLOBAL MOLECULAR DIAGNOSTICS MARKET REVENUE IN OTHER SEGMENTS, 2017–2024 ($MILLION) 44
CHART 17 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY END-USERS SEGMENTATION, 2017 (%) 45
CHART 18 GLOBAL MOLECULAR DIAGNOSTICS MARKET BY GEOGRAPHICAL SEGMENTATION, 2017 (%) 48
CHART 19 MOLECULAR DIAGNOSTICS MARKET REVENUE IN NORTH AMERICA, 2017–2024 ($MILLION) 50
CHART 20 MOLECULAR DIAGNOSTICS MARKET REVENUE IN THE US, 2017–2024 ($MILLION) 52
CHART 21 US MOLECULAR DIAGNOSTICS MARKET BY TECHNOLOGY SEGMENTATION, 2017 (%) 54
CHART 22 US MOLECULAR DIAGNOSTICS MARKET BY APPLICATION SEGMENTATION, 2017 (%) 56
CHART 23 MOLECULAR DIAGNOSTICS MARKET REVENUE IN EUROPE, 2017–2024 ($MILLION) 57
CHART 24 MOLECULAR DIAGNOSTICS MARKET REVENUE IN ASIA PACIFIC, 2017–2024 ($MILLION) 59
CHART 25 REST OF THE WORLD MARKET REVENUE IN REST OF THE WORLD, 2017–2024 ($MILLION) 62
CHART 26 DANAHER CORPORATION: OVERVIEW SNAPSHOT 70
CHART 27 DANAHER CORPORATION: BUSINESS UNITS 71
CHART 28 DANAHER CORPORATION: GEOGRAPHIC PRESENCE 72
CHART 29 DANAHER CORPORATION: SWOT ANALYSIS 73
CHART 30 F. HOFFMANN-LA ROCHE LTD.: OVERVIEW SNAPSHOT 81
CHART 31 F. HOFFMANN-LA ROCHE LTD.: BUSINESS UNITS 82
CHART 32 F. HOFFMANN-LA ROCHE LTD.: GEOGRAPHIC REVENUE 82
CHART 33 F. HOFFMANN-LA ROCHE LTD.: SWOT ANALYSIS 84
CHART 34 ABBOTT LABORATORIES: OVERVIEW SNAPSHOT 89
CHART 35 ABBOTT LABORATORIES.: BUSINESS UNITS 90
CHART 36 ABBOTT LABORATORIES: GEOGRAPHIC PRESENCE 91
CHART 37 ABBOTT LABORATORIES: SWOT ANALYSIS 92
CHART 38 HOLOGIC INC.: OVERVIEW SNAPSHOT 96
CHART 39 HOLOGIC INC.: BUSINESS UNITS 97
CHART 40 HOLOGIC INC: GEOGRAPHIC PRESENCE 98
CHART 41 HOLOGIC, INC.: SWOT ANALYSIS 99
CHART 42 SIEMENS AG: OVERVIEW SNAPSHOT 103
CHART 43 SIEMENS AG: BUSINESS UNITS 104
CHART 44 SIEMENS AG: GEOGRAPHIC PRESENCE 105
CHART 45 SIEMENS HEALTHINEERS: SWOT ANALYSIS 106

None

growing application segment during the forecast period.
Key Players: F. Hoffmann-La Roche, Hologic, Inc., Danaher Corporation, Abbott Laboratories, and Siemens Healthineers Inc. are the key players in the market. Becton Dickenson and Company, bioMerieux S.A., Bio-Rad Laboratories, Inc., Qiagen NV, Grifols, S.A, Thermo Fisher Scientific, Sysmex Corporation, and Myriad Genetics

Custom Research

Looking for more specific research study and analysis? Contact our Custom Research Team

Write to Custom Research Team